The proliferation of new drugs in ophthalmology is both exciting and challenging. Exciting because there are more options to offer patients, and challenging because there are changes and nuances that must be mastered to ensure that reimbursement is received for these new treatment options. Successful reimbursement centers around accurate and comprehensive documentation. In this article, we will review the basic documentation standards, provide updates on documentation and coding for recently approved medications, and review revised coding information for several existing medications.